Skip to Content
Merck
  • Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation.

Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation.

Proceedings of the National Academy of Sciences of the United States of America (2007-12-29)
Zenggang Li, Jing Zhao, Yuhong Du, Hae Ryoun Park, Shi-Yong Sun, Leon Bernal-Mizrachi, Alastair Aitken, Fadlo R Khuri, Haian Fu
ABSTRACT

The family of 14-3-3 proteins has emerged as critical regulators of diverse cellular responses under both physiological and pathological conditions. Here, we report an important role of 14-3-3zeta in tumorigenesis through a mechanism that involves anoikis resistance. 14-3-3zeta is up-regulated in a number of cancer types, including lung cancer. Through an RNAi approach using human lung adenocarcinoma-derived A549 cells as a model system, we have found that knockdown of a single zeta isoform of 14-3-3 is sufficient to restore the sensitivity of cancer cells to anoikis and impair their anchorage-independent growth. Enhanced anoikis appears to be mediated in part by up-regulated BH3-only proteins, Bad and Bim, coupled with decreased Mcl-1, resulting in the subsequent activation of Bax. This study suggests a model in which anchorage-independent growth of lung cancer cells requires the presence of 14-3-3zeta. This work not only reveals a critical role of 14-3-3zeta in anoikis suppression in lung cancer cells, but also identifies and validates 14-3-3zeta as a potential molecular target for anticancer therapeutic development.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
14-3-3 ζ, untagged human, recombinant, expressed in E. coli, ≥70% (SDS-PAGE), buffered aqueous glycerol solution